The European Medicines Agency (EMEA) has concluded that updated warnings to doctors and patients are needed to increase awareness of cases of suicidal ideation and suicide attempts reported in patients using Champix (varenicline), a medicine indicated for smoking cessation in adults. The Committee for Medicinal Products for Human Use (CHMP) has been closely monitoring the safety of Champix since it was first authorised in the European Union (EU) in September 2006. [click link for full article]
Popularity: 1% [?]
Related posts:
- European Medicines Agency Concludes New Advice To Doctors And Patientsfor Champix Needed
- European Medicines Agency Recommends Acomplia Must Not Be Used In Patients On Antidepressants Or With Major Depression
- Novel Antidepressant Valdoxan(R), Receives EMEA CHMP Positive Opinion For Major Depressive Episodes
- European Medicines Agency Adopts Positive Opinion For Use Of Prozac For Children And Adolescents Suffering From Depression
- Europe Wants Warnings On Champix Smoking Cessation Drug
Comments
No Responses to “European Medicines Agency Concludes New Advice To Doctors And Patientsfor Champix Needed”